These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31742915)

  • 41. U.S. v. Barr Laboratories: a technical perspective.
    Madsen RE
    PDA J Pharm Sci Technol; 1994; 48(4):176-9. PubMed ID: 7804814
    [No Abstract]   [Full Text] [Related]  

  • 42. International Conference on Harmonisation; addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2012 May; 77(97):29665-6. PubMed ID: 22616137
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toward more effective drug regulation.
    Schmidt AM
    FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532
    [No Abstract]   [Full Text] [Related]  

  • 44. Response to the applicability of proposed large volume parenteral regulations to small volume parenteral drug products.
    Bull Parenter Drug Assoc; 1976; 30(6):265-79. PubMed ID: 1000103
    [No Abstract]   [Full Text] [Related]  

  • 45. Preclearance of drug products--pharmacy's perspective.
    Feldmann EG
    Am Pharm; 1981 Jun; NS21(6):26-32. PubMed ID: 7246421
    [No Abstract]   [Full Text] [Related]  

  • 46. [European legislation on biological similarity recommendations of the European Agency on Medications concerning drug quality].
    Prugnaud JL
    Nephrol Ther; 2009 Feb; 5 Spec No1():3-5. PubMed ID: 19233075
    [No Abstract]   [Full Text] [Related]  

  • 47. FDA seeks comments on compounding guide.
    Young D
    Am J Health Syst Pharm; 2002 Jul; 59(14):1318. PubMed ID: 12132553
    [No Abstract]   [Full Text] [Related]  

  • 48. Ethics. Clinical trials guidelines at odds with U.S. policy.
    Normile D
    Science; 2008 Oct; 322(5901):516. PubMed ID: 18948510
    [No Abstract]   [Full Text] [Related]  

  • 49. China's perspective on similar biotherapeutic products.
    Liang C; Wang J
    Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current development in regulation of similar biotherapeutic products in Brazil.
    Castanheira LG; Barbano DB; Rech N
    Biologicals; 2011 Sep; 39(5):308-11. PubMed ID: 21868247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical trials and the drug review process.
    Schmidt AM
    Chest; 1978 Jun; 73(6 Suppl):967-71. PubMed ID: 354887
    [No Abstract]   [Full Text] [Related]  

  • 52. FDA regulation of drugs, devices.
    Radzius JR
    AORN J; 1976 Aug; 24(2):254-5, 258-9, 262-3. PubMed ID: 1047997
    [No Abstract]   [Full Text] [Related]  

  • 53. Present attitudes of governmental drug regulatory agencies.
    Noel PR
    Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283
    [No Abstract]   [Full Text] [Related]  

  • 54. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
    Meron D
    Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
    [No Abstract]   [Full Text] [Related]  

  • 55. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 56. ICH E9 guideline 'Statistical principles for clinical trials': a case study.
    Phillips A; Haudiquet V
    Stat Med; 2003 Jan; 22(1):1-11; discussion 13-7. PubMed ID: 12486747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quality assurance of drugs used in clinical trials: proposal for adapting guidelines.
    Newton PN; Schellenberg D; Ashley EA; Ravinetto R; Green MD; ter Kuile FO; Tabernero P; White NJ; Guerin PJ
    BMJ; 2015 Feb; 350():h602. PubMed ID: 25716700
    [No Abstract]   [Full Text] [Related]  

  • 58. FDA, states discuss pharmacy compounding regulatory framework.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(3):180, 182. PubMed ID: 23327976
    [No Abstract]   [Full Text] [Related]  

  • 59. Secondary wholesalers oppose FDA pedigree regulation.
    Young D
    Am J Health Syst Pharm; 2001 Sep; 58(18):1698, 1700. PubMed ID: 11571811
    [No Abstract]   [Full Text] [Related]  

  • 60. Improving safety, quality and efficacy of medicines in the Americas.
    Bolaños R; Bond K; Child R; Coto JV; Cummings R; Dellepiane N; Fitzgerald J; Parker C; Pereira P; Sánchez Y Tépoz J; Stergachis A
    Rev Panam Salud Publica; 2016 May; 39(5):215-216. PubMed ID: 27706408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.